PRT12396 (JAK2V617F mutant-selective JH2 inhibitor)

Current understanding

To be populated as evidence accumulates.

Evidence log

• December 6 — Prelude Therapeutics Presents Data at 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs: ASH 2025 (preclinical): Prelude Therapeutics presented data showing PRT12396, a JAK2V617F-selective JH2 pseudokinase domain inhibitor, achieves robust anti-MPN activity superior to ruxolitinib across multiple preclinical MPN models while sparing wild-type JAK2-mediated cytokine signaling; GLP toxicology completed and IND/Phase 1 initiation anticipated Q1 2026. (novelty: 4)

Open questions

Related